abilify and semaglutide Primary structure of (a) (b) liraglutide. Aib, FDA Warns Abilify Can Cause

Survodutide (BI-456906) is an investigational dual agonist targeting: GLP-1 receptors , which regulate appetite, gastric emptying, and glucose metabolism Glucagon receptors , which influence energy expenditure, fat oxidation, and hepatic metabolism Unlike GLP-1only therapies, survodutide is designed to influence both intake and metabolic output

However, the evidence is limited and the effect size is small

Chrononutritional strategies, including time-restricted feeding (TRF), are discussed primarily as lifestyle interventions designed to enhance circadian alignment and metabolic resilience in the general population and during aging

Sweating, palpitations, and tremor may also occur, particularly if hypoglycaemia is present, and positional dizziness on standing suggests orthostatic hypotension